![spot light](/PHGKB/images/spotlight2.jpg)
Harnessing cancer genomes for precision oncology
The State of State Biomarker Testing Insurance Coverage Laws
Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies.
Ariadna Tibau et al. JAMA Oncol 2024 4
Deep learning in cancer genomics and histopathology
M Unger et al, Genome Medicine, March 27, 2024
Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source: